Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7.03M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
5.22M
-
Shares change
-
+319K
-
Total reported value, excl. options
-
$188M
-
Value change
-
+$11.6M
-
Number of buys
-
19
-
Number of sells
-
-15
-
Price
-
$36.07
Significant Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Stock (DRUG) as of Q1 2025
41 filings reported holding DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Stock as of Q1 2025.
BRIGHT MINDS BIOSCIENCES INC. - Common Stock (DRUG) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.22M shares
of 7.03M outstanding shares and own 74.23% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.11M shares), Cormorant Asset Management, LP (1.06M shares), Sio Capital Management, LLC (508K shares), COMMODORE CAPITAL LP (500K shares), PERCEPTIVE ADVISORS LLC (445K shares), Vivo Capital, LLC (252K shares), RA CAPITAL MANAGEMENT, L.P. (206K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (200K shares), MILLENNIUM MANAGEMENT LLC (193K shares), and MORGAN STANLEY (157K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.